Advertisement

Evolution of oncosurgical management of pancreatic cancer

  • Ulla Klaiber
  • Susanne Roth
  • Thilo Hackert
  • John P. NeoptolemosEmail author
main topic
  • 10 Downloads

Summary

Background

Pancreatic cancer is the third leading cause of cancer-related death in the Western world and is projected to soon become the second commonest cause of cancer mortality. During the past two decades, there have been important clinical developments in the fight against this aggressive disease.

Objective

The aim of this review article is to summarize the evolution of the multidisciplinary oncological and surgical management of pancreatic cancer.

Results

The centralization of pancreatic surgery into specialized institutions has led to improvements in surgical techniques, with reduced surgical mortality rates of <5%. With the development of more effective neoadjuvant treatment options, we can now achieve resections in a considerably greater number of patients with borderline resectable and locally advanced tumors, including some with oligometastatic disease. New surgical technologies such as laparoscopic and robotic surgery may offer the opportunity for reduced postoperative morbidity and increased quality of life. Adjuvant chemotherapy has become the gold standard after upfront resection in patients with resectable pancreatic cancer yielding survival times of 30–50% at 5 years. The ESPAC-1, -3, and -4 trials have defined the efficacy of monotherapy with 5‑fluorouracil/folinic acid and gemcitabine, and combination therapy with gemcitabine and capecitabine, respectively, whilst the PRODIGE 24/CCTG PA.6 trial showed that poly-agent FOLFIRINOX achieved a median survival of 54.4 months in selected patients.

Conclusion

With the utilization of more effective neoadjuvant and adjuvant treatment regimens, improvements in surgical techniques, and the centralization of pancreatic surgery, the indications for pancreatic resection with improved survival have been greatly extended.

Keywords

Pancreatic surgery Adjuvant therapy Neoadjuvant therapy ESPAC FOLFIRINOX APACT 

Notes

Conflict of interest

U. Klaiber, S. Roth, T. Hackert, and J.P. Neoptolemos declare that they have no competing interests.

References

  1. 1.
    Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. IEEE Trans Med Imaging. 2018;68(6):394:424.Google Scholar
  2. 2.
    Neoptolemos JP, Kleeff J, Michl P, Costello E, Greenhalf W, Palmer DH. Therapeutic developments in pancreatic cancer: current and future perspectives. Nat Rev Gastroenterol Hepatol. 2018;15(6):333–48.CrossRefGoogle Scholar
  3. 3.
    Buchler MW, Wagner M, Schmied BM, Uhl W, Friess H, Z’Graggen K. Changes in morbidity after pancreatic resection: toward the end of completion pancreatectomy. Archives of surgery (Chicago, Ill: 1960). 2003;138(12):1310–4; discussion 5.Google Scholar
  4. 4.
    Huttner FJ, Capdeville L, Pianka F, Ulrich A, Hackert T, Buchler MW, et al. Systematic review of the quantity and quality of randomized clinical trials in pancreatic surgery. Br J Surg. 2019;106(1):23–31.CrossRefGoogle Scholar
  5. 5.
    Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011–24.CrossRefGoogle Scholar
  6. 6.
    Conroy T, Hammel P, Hebbar M, Abdelghani BM, Wei AC, Raoul JL, et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med. 2018;379(25):2395–406.CrossRefGoogle Scholar
  7. 7.
    Ricci C, Casadei R, Taffurelli G, Pacilio CA, Ricciardiello M, Minni F. Minimally Invasive Pancreaticoduodenectomy: What is the Best “Choice”? A Systematic Review and Network Meta-analysis of Non-randomized Comparative Studies. World J Surg. 2018;42(3):788–805.CrossRefGoogle Scholar
  8. 8.
    Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, et al. Pancreatic cancer. Nat Rev Dis Primers. 2016;2:16022.CrossRefGoogle Scholar
  9. 9.
    Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006;13(8):1035–46.CrossRefGoogle Scholar
  10. 10.
    Vauthey JN, Dixon E. AHPBA/SSO/SSAT Consensus Conference on Resectable and Borderline Resectable Pancreatic Cancer: rationale and overview of the conference. Ann Surg Oncol. 2009;16(7):1725–6.CrossRefGoogle Scholar
  11. 11.
    Bockhorn M, Uzunoglu FG, Adham M, Imrie C, Milicevic M, Sandberg AA, et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2014;155(6):977–88.CrossRefGoogle Scholar
  12. 12.
    Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, et al. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN. 2017;15(8):1028–61.CrossRefGoogle Scholar
  13. 13.
    Klaiber U, Mihaljevic A, Hackert T. Radical pancreatic cancer surgery—with arterial resection. Translational Gastroenterology and. Hepatology. 2019.  https://doi.org/10.21037/tgh.2019.01.07.CrossRefGoogle Scholar
  14. 14.
    Loizou L, Duran CV, Axelsson E, Andersson M, Keussen I, Strinnholm J, et al. Radiological assessment of local resectability status in patients with pancreatic cancer: Interreader agreement and reader performance in two different classification systems. Eur J Radiol. 2018;106:69–76.CrossRefGoogle Scholar
  15. 15.
    Bramhall SR, Allum WH, Jones AG, Allwood A, Cummins C, Neoptolemos JP. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. The British journal of surgery. 1995;82(1):111–5.CrossRefGoogle Scholar
  16. 16.
    Neoptolemos JP, Russell RC, Bramhall S, Theis B. Low mortality following resection for pancreatic and periampullary tumours in 1026 patients: UK survey of specialist pancreatic units. UK Pancreatic Cancer Group. Br J Surg. 1997;84(10):1370–6.CrossRefGoogle Scholar
  17. 17.
    Guidance on Commissioning Cancer Services Improving Outcomes in Upper Gastro-intestinal Cancers. January 2001. Department of Health PO Box 777. London. SE1 6XH, UK.Google Scholar
  18. 18.
    Birkmeyer JD, Siewers AE, Finlayson EV, Stukel TA, Lucas FL, Batista I, et al. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;346(15):1128–37.CrossRefGoogle Scholar
  19. 19.
    Lidsky ME, Sun Z, Nussbaum DP, Adam MA, Speicher PJ, Blazer DG 3rd. Going the Extra Mile: Improved Survival for Pancreatic Cancer Patients Traveling to High-volume Centers. Ann Surg. 2017;266(2):333–8.CrossRefGoogle Scholar
  20. 20.
    Mehrabi A, Hafezi M, Arvin J, Esmaeilzadeh M, Garoussi C, Emami G, et al. A systematic review and meta-analysis of laparoscopic versus open distal pancreatectomy for benign and malignant lesions of the pancreas: it’s time to randomize. Surgery. 2015;157(1):45–55.CrossRefGoogle Scholar
  21. 21.
    Riviere D, Gurusamy KS, Kooby DA, Vollmer CM, Besselink MG, Davidson BR, et al. Laparoscopic versus open distal pancreatectomy for pancreatic cancer. Cochrane Database Syst Rev. 2016;4:Cd11391.PubMedGoogle Scholar
  22. 22.
    van Hilst J, de Rooij T, Klompmaker S, Rawashdeh M, Aleotti F, Al-Sarireh B, et al. Minimally Invasive versus Open Distal Pancreatectomy for Ductal Adenocarcinoma (DIPLOMA): A Pan-European Propensity Score Matched Study. Ann Surg. 2019;269(1):10–7.CrossRefGoogle Scholar
  23. 23.
    de Rooij T, Lu MZ, Steen MW, Gerhards MF, Dijkgraaf MG, Busch OR, et al. Minimally Invasive Versus Open Pancreatoduodenectomy: Systematic Review and Meta-analysis of Comparative Cohort and Registry Studies. Ann Surg. 2016;264(2):257–67.CrossRefGoogle Scholar
  24. 24.
    Sharpe SM, Talamonti MS, Wang CE, Prinz RA, Roggin KK, Bentrem DJ, et al. Early National Experience with Laparoscopic Pancreaticoduodenectomy for Ductal Adenocarcinoma: A Comparison of Laparoscopic Pancreaticoduodenectomy and Open Pancreaticoduodenectomy from the National Cancer Data Base. J Am Coll Surg. 2015;221(1):175–84.CrossRefGoogle Scholar
  25. 25.
    van Hilst J, de Rooij T, Bosscha K, Brinkman DJ, van Dieren S, Dijkgraaf MG, et al. Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2/3 trial. Lancet Gastroenterol Hepatol. 2019.  https://doi.org/10.1016/S2468-1253(19)30004-4.CrossRefPubMedGoogle Scholar
  26. 26.
    Hartwig W, Werner J, Jager D, Debus J, Buchler MW. Improvement of surgical results for pancreatic cancer. Lancet Oncol. 2013;14(11):e476–e85.CrossRefGoogle Scholar
  27. 27.
    Harnoss JC, Ulrich AB, Harnoss JM, Diener MK, Buchler MW, Welsch T. Use and results of consensus definitions in pancreatic surgery: a systematic review. Surgery. 2014;155(1):47–57.CrossRefGoogle Scholar
  28. 28.
    Sanjay P, Kellner M, Tait IS. The role of interventional radiology in the management of surgical complications after pancreatoduodenectomy. HPB: the official journal of the International Hepato Pancreato Biliary. Association. 2012;14(12):812–7.Google Scholar
  29. 29.
    Hackert T, Klaiber U, Hinz U, Kehayova T, Probst P, Knebel P, et al. Sphincter of Oddi botulinum toxin injection to prevent pancreatic fistula after distal pancreatectomy. Surgery. 2017;161(5):1444–50.CrossRefGoogle Scholar
  30. 30.
    Van Buren G 2nd, Bloomston M, Hughes SJ, Winter J, Behrman SW, Zyromski NJ, et al. A randomized prospective multicenter trial of pancreaticoduodenectomy with and without routine intraperitoneal drainage. Ann Surg. 2014;259(4):605–12.CrossRefGoogle Scholar
  31. 31.
    Witzigmann H, Diener MK, Kienkotter S, Rossion I, Bruckner T, Barbel W, et al. No Need for Routine Drainage After Pancreatic Head Resection: The Dual-Center, Randomized, Controlled PANDRA Trial (ISRCTN04937707). Ann Surg. 2016;264(3):528–37.CrossRefGoogle Scholar
  32. 32.
    Xourafas D, Ejaz A, Tsung A, Dillhoff M, Pawlik TM, Cloyd JM. Population-Based Assessment of Selective Drain Placement During Pancreatoduodenectomy Using the Modified Fistula Risk Score. J Am Coll Surg. 2018.  https://doi.org/10.1016/j.jamcollsurg.CrossRefPubMedGoogle Scholar
  33. 33.
    Diener MK, Seiler CM, Rossion I, Kleeff J, Glanemann M, Butturini G, et al. Efficacy of stapler versus hand-sewn closure after distal pancreatectomy (DISPACT): a randomised, controlled multicentre trial. Lancet. 2011;377(9776):1514–22.CrossRefGoogle Scholar
  34. 34.
    Klaiber U, Leonhardt CS, Strobel O, Tjaden C, Hackert T, Neoptolemos JP. Neoadjuvant and adjuvant chemotherapy in pancreatic cancer. Langenbeck’s. Arch Surg. 2018;403(8):917–32.CrossRefGoogle Scholar
  35. 35.
    Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001;358(9293):1576–85.CrossRefGoogle Scholar
  36. 36.
    Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350(12):1200–10.CrossRefGoogle Scholar
  37. 37.
    Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304(10):1073–81.CrossRefGoogle Scholar
  38. 38.
    Ghaneh P, Kleeff J, Halloran CM, Raraty M, Jackson R, Melling J, et al. The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. Ann Surg. 2017.  https://doi.org/10.1097/SLA.0000000000002557.CrossRefGoogle Scholar
  39. 39.
  40. 40.
    Hackert T, Sachsenmaier M, Hinz U, Schneider L, Michalski CW, Springfeld C, et al. Locally Advanced Pancreatic Cancer: Neoadjuvant Therapy With Folfirinox Results in Resectability in 60% of the Patients. Ann Surg. 2016;264(3):457–63.CrossRefGoogle Scholar
  41. 41.
    Murphy JE, Wo JY, Ryan DP, Jiang W, Yeap BY, Drapek LC, et al. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial. Jama Oncol. 2018;4(7):963–9.CrossRefGoogle Scholar
  42. 42.
    Golcher H, Brunner TB, Witzigmann H, Marti L, Bechstein WO, Bruns C, et al. Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al]. 2015;191(1):7–16.Google Scholar
  43. 43.
    Casadei R, Di Marco M, Ricci C, Santini D, Serra C, Calculli L, et al. Neoadjuvant Chemoradiotherapy and Surgery Versus Surgery Alone in Resectable Pancreatic Cancer: A Single-Center Prospective, Randomized, Controlled Trial Which Failed to Achieve Accrual Targets. Journal of gastrointestinal surgery: official journal of the Society for Surgery of the Alimentary Tract. 2015;19(10):1802–12.CrossRefGoogle Scholar
  44. 44.
    Van Tienhoven G SM, Groothuis KB, Busch OR, Bonsing BA de Hingh IH, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): A randomized, controlled, multicenter phase III trial. Journal Clinical Oncology 36, abstr. LBA4002 (2018).Google Scholar
  45. 45.
    Unno M, Motoi F, Matsuyama Y, Satoi S, Matsumoto I, Aosasa S, et al. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S‑1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP-05). Journal of Clinical Oncology. 2019;37(4_suppl):189–.CrossRefGoogle Scholar
  46. 46.
    Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, et al. Adjuvant chemotherapy of S‑1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388(10041):248–57.CrossRefGoogle Scholar
  47. 47.
    Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.CrossRefGoogle Scholar
  48. 48.
    Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703.CrossRefGoogle Scholar
  49. 49.
    Kunzmann V, Ramanathan RK, Goldstein D, Liu H, Ferrara S, Lu B, Renschler MF, et al. Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine: An Exploratory Analysis From a Phase 3 Study. Pancreas. 2017;46(2):203–8.CrossRefGoogle Scholar
  50. 50.
    ESPAC-5F: European Study Group for Pancreatic Cancer—Trial 5F.  https://doi.org/10.1186/ISRCTN89500674
  51. 51.
    Marquart J, Chen EY, Prasad V. Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology. Jama Oncol. 2018;4(8:1093–8.CrossRefGoogle Scholar
  52. 52.
    Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011;17(4):500–3.CrossRefGoogle Scholar
  53. 53.
    Moffitt RA, Marayati R, Flate EL, Volmar KE, Loeza SG, Hoadley KA, et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet. 2015;47(10):1168–78.CrossRefGoogle Scholar
  54. 54.
    Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518(7540):495–501.CrossRefGoogle Scholar
  55. 55.
    Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531(7592):47–52.CrossRefGoogle Scholar
  56. 56.
    Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer cell. 2017;32(2):185–203.e13.Google Scholar
  57. 57.
    Notta F, Chan-Seng-Yue M, Lemire M, Li Y, Wilson GW, Connor AA, et al. A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. Nature. 2016;538(7625):378–82.CrossRefGoogle Scholar
  58. 58.
    Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science (New York, NY). 2017;357(6349):409–13.Google Scholar
  59. 59.
    Ostrem JM, Peters U, Sos ML, Wells JA, K‑Ras SKM. (G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013;503(7477):548–51.CrossRefGoogle Scholar
  60. 60.
    Heining C, Horak P, Uhrig S, Codo PL, Klink B, Hutter B. et al. NRG1 Fusions in KRAS Wild-type Pancreatic Cancer. Cancer Discov. 2018.  https://doi.org/10.1158/2159-8290.CD-18-0036.CrossRefPubMedGoogle Scholar
  61. 61.
    Aung KL, Fischer SE, Denroche RE, Jang GH, Dodd A, Creighton S, et al. Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial. Clinical cancer research: an official journal of the American Association for. Cancer Res. 2018;24(6):1344–54.Google Scholar
  62. 62.
    Aguirre AJ, Nowak JA, Camarda ND, Moffitt RA, Ghazani AA, Hazar-Rethinam M, et al. Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine. Cancer Discov. 2018.  https://doi.org/10.1158/2159-8290.CD-18-0275.CrossRefPubMedGoogle Scholar
  63. 63.
    Tiriac H, Belleau P, Engle DD, Plenker D, Deschenes A, Somerville T, et al. Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. Cancer Discov. 2018.  https://doi.org/10.1158/2159-8290.CD-18-0349.CrossRefPubMedGoogle Scholar
  64. 64.
    Friedman AA, Letai A, Fisher DE, Flaherty KT. Precision medicine for cancer with next-generation functional diagnostics. Nat Rev Cancer. 2015;15(12):747–56.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2019

Authors and Affiliations

  • Ulla Klaiber
    • 1
  • Susanne Roth
    • 1
  • Thilo Hackert
    • 1
  • John P. Neoptolemos
    • 1
    Email author
  1. 1.Department of General, Visceral and Transplantation SurgeryUniversity of HeidelbergHeidelbergGermany

Personalised recommendations